Tactile Systems Technology, Inc. (TCMD) reported first‑quarter 2026 revenue of $75.3 million, a 23% year‑over‑year increase that exceeded the consensus estimate of $70.6 million. The lift was driven by strong demand in both the lymphedema and airway‑clearance segments, with lymphedema revenue reaching $62.2 million and airway‑clearance revenue at $13 million. The company’s expanded sales force and AI‑enabled documentation systems helped capture additional market share, while the Medicare prior‑authorization rollout for pneumatic compression devices added a new revenue channel.
The company posted a net loss of $1.8 million, or $0.08 per diluted share, compared with a $3.0 million loss in the same period last year. The loss per share fell short of the consensus estimate of $0.07, a miss of $0.01, reflecting higher operating expenses. Gross profit rose to $57.6 million, giving a gross margin of 76.5% versus 74% in Q1 2025. The margin expansion was largely due to a favorable product and payer mix, lower manufacturing costs, and stronger collections, offsetting the impact of higher sales, marketing, R&D, and G&A expenses that pushed operating expenses to $59.1 million and produced an operating loss of $1.5 million.
Adjusted EBITDA turned positive at $3.7 million, a turnaround from the $0.3 million loss reported in Q1 2025. The improvement reflects the company’s ability to generate operating leverage as revenue scales, while the higher operating expenses are driven by investments in technology, sales, and marketing to support the newly acquired LymphaTech and the rollout of its AI platform for Medicare prior authorization. The company reiterated its 2026 revenue guidance of $360 million to $368 million and adjusted EBITDA guidance of $49 million to $51 million, maintaining confidence in the near‑term outlook. The guidance was unchanged from the prior estimate, indicating management’s belief that the current growth trajectory will continue.
Management highlighted that the LymphaTech acquisition, closed for $7.2 million in cash plus contingent consideration, adds 3D measurement technology and goodwill, expanding the company’s product portfolio and strengthening its position in the lymphedema market. The company also received FDA 510(k) clearance for its next‑generation AffloVest airway‑clearance device, positioning it to capture a larger share of the airway‑clearance market. The Medicare prior‑authorization rollout, which began on April 13, has already driven a 40% year‑over‑year increase in Medicare‑channel sales, providing a tailwind for future revenue growth.
Investors reacted cautiously to the earnings release. While the revenue beat and margin expansion were positive signals, the EPS miss and continued net loss tempered enthusiasm. Analysts noted that the company’s guidance remains unchanged, suggesting that management is confident in sustaining the current growth path but remains mindful of the higher operating costs associated with its expansion and regulatory compliance efforts.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.